NEKTAR THERAPEUTICS — Director's Dealing 2012

Apr 11, 2012

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: NEKTAR THERAPEUTICS (NKTR)
CIK: 0000906709
Period of Report: 2012-04-04

Reporting Person: Medve Robert (Chief Medical Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Employee Stock Option	$9.47	2019-03-30	Common Stock (76500)		Direct
Employee Stock Option	$7.55	2019-06-12	Common Stock (23500)		Direct
Employee Stock Option	$7.21	2020-02-07	Common Stock (75000)		Direct
Employee Stock Option	$7.21	2020-02-07	Common Stock (75000)		Direct

Footnotes

F1: This option was granted on March 31, 2011 and vests as to 25% of the option on the first anniversary of the grant date and as to the remaining 75% of the option in monthly installments over the three-year period thereafter.

F2: This option was granted on June 13, 2011 and vests in monthly installments over the four-year period following the grant date.

F3: This option was granted on February 8, 2012 and vests in monthly installments over the four-year period following the grant date.

F4: This option was granted on February 8, 2012 and is subject to both time-based vesting and performance-based vesting conditions, both of which must be met before the option becomes vested and exerciseable. Under the time-based vesting requirement, the option vests in monthly installments over the four-year period following the grant date. The performance-based vesting condition will be met only if Nektar (or a licensee), within 5 years following the grant date, files a new drug registration with the U.S. FDA or the European Medicines Agency for a significant drug candidate program.